Cargando…
The SARS-CoV-2 mutations versus vaccine effectiveness: New opportunities to new challenges
BACKGROUND: The SARS-CoV-2 coronavirus epidemic is hastening the discovery of the most efficient vaccines. The development of cost-effective vaccines seems to be the only solution to terminate this pandemic. However, the vaccines’ effectiveness has been questioned due to recurrent mutations in the S...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Author(s). Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8730674/ https://www.ncbi.nlm.nih.gov/pubmed/35042059 http://dx.doi.org/10.1016/j.jiph.2021.12.014 |
_version_ | 1784627186738659328 |
---|---|
author | Malik, Jonaid Ahmad Ahmed, Sakeel Mir, Aroosa Shinde, Mrunal Bender, Onur Alshammari, Farhan Ansari, Mukhtar Anwar, Sirajudheen |
author_facet | Malik, Jonaid Ahmad Ahmed, Sakeel Mir, Aroosa Shinde, Mrunal Bender, Onur Alshammari, Farhan Ansari, Mukhtar Anwar, Sirajudheen |
author_sort | Malik, Jonaid Ahmad |
collection | PubMed |
description | BACKGROUND: The SARS-CoV-2 coronavirus epidemic is hastening the discovery of the most efficient vaccines. The development of cost-effective vaccines seems to be the only solution to terminate this pandemic. However, the vaccines’ effectiveness has been questioned due to recurrent mutations in the SARS-CoV-2 genome. Most of the mutations are associated with the spike protein, a vital target for several marketed vaccines. Many countries were highly affected by the 2nd wave of the SARS-CoV-2, like the UK, India, Brazil and France. Experts are also alarming the further COVID-19 wave with the emergence of Omicron, which is highly affecting the South African populations. This review encompasses the detailed description of all vaccine candidates and COVID-19 mutants that will add value to design further studies to combat the COVID-19 pandemic. METHODS: The information was generated using various search engines like google scholar, PubMed, clinicaltrial.gov.in, WHO database, ScienceDirect, and news portals by using keywords SARS-CoV-2 mutants, COVID-19 vaccines, efficacy of SARS-CoV-2 vaccines, COVID-19 waves. RESULTS: This review has highlighted the evolution of SARS-CoV-2 variants and the vaccine efficacy. Currently, various vaccine candidates are undergoing several phases of development. Their efficacy still needs to check for newly emerged variants. We have focused on the evolution, multiple mutants, waves of the SARS-CoV-2, and different marketed vaccines undergoing various clinical trials and the design of the trials to determine vaccine efficacy. CONCLUSION: Various mutants of SARS-CoV-2 arrived, mainly concerned with the spike protein, a key component to design the vaccine candidates. Various vaccines are undergoing clinical trial and show impressive results, but their efficacy still needs to be checked in different SARS-CoV-2 mutants. We discussed all mutants of SARS-CoV-2 and the vaccine’s efficacy against them. The safety concern of these vaccines is also discussed. It is important to understand how coronavirus gets mutated to design better new vaccines, providing long-term protection and neutralizing broad mutant variants. A proper study approach also needs to be considered while designing the vaccine efficacy trials, which further improved the study outcomes. Taking preventive measures to protect from the virus is also equally important, like vaccine development. |
format | Online Article Text |
id | pubmed-8730674 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | The Author(s). Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences. |
record_format | MEDLINE/PubMed |
spelling | pubmed-87306742022-01-06 The SARS-CoV-2 mutations versus vaccine effectiveness: New opportunities to new challenges Malik, Jonaid Ahmad Ahmed, Sakeel Mir, Aroosa Shinde, Mrunal Bender, Onur Alshammari, Farhan Ansari, Mukhtar Anwar, Sirajudheen J Infect Public Health Review BACKGROUND: The SARS-CoV-2 coronavirus epidemic is hastening the discovery of the most efficient vaccines. The development of cost-effective vaccines seems to be the only solution to terminate this pandemic. However, the vaccines’ effectiveness has been questioned due to recurrent mutations in the SARS-CoV-2 genome. Most of the mutations are associated with the spike protein, a vital target for several marketed vaccines. Many countries were highly affected by the 2nd wave of the SARS-CoV-2, like the UK, India, Brazil and France. Experts are also alarming the further COVID-19 wave with the emergence of Omicron, which is highly affecting the South African populations. This review encompasses the detailed description of all vaccine candidates and COVID-19 mutants that will add value to design further studies to combat the COVID-19 pandemic. METHODS: The information was generated using various search engines like google scholar, PubMed, clinicaltrial.gov.in, WHO database, ScienceDirect, and news portals by using keywords SARS-CoV-2 mutants, COVID-19 vaccines, efficacy of SARS-CoV-2 vaccines, COVID-19 waves. RESULTS: This review has highlighted the evolution of SARS-CoV-2 variants and the vaccine efficacy. Currently, various vaccine candidates are undergoing several phases of development. Their efficacy still needs to check for newly emerged variants. We have focused on the evolution, multiple mutants, waves of the SARS-CoV-2, and different marketed vaccines undergoing various clinical trials and the design of the trials to determine vaccine efficacy. CONCLUSION: Various mutants of SARS-CoV-2 arrived, mainly concerned with the spike protein, a key component to design the vaccine candidates. Various vaccines are undergoing clinical trial and show impressive results, but their efficacy still needs to be checked in different SARS-CoV-2 mutants. We discussed all mutants of SARS-CoV-2 and the vaccine’s efficacy against them. The safety concern of these vaccines is also discussed. It is important to understand how coronavirus gets mutated to design better new vaccines, providing long-term protection and neutralizing broad mutant variants. A proper study approach also needs to be considered while designing the vaccine efficacy trials, which further improved the study outcomes. Taking preventive measures to protect from the virus is also equally important, like vaccine development. The Author(s). Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences. 2022-02 2022-01-05 /pmc/articles/PMC8730674/ /pubmed/35042059 http://dx.doi.org/10.1016/j.jiph.2021.12.014 Text en © 2022 The Author(s) Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Review Malik, Jonaid Ahmad Ahmed, Sakeel Mir, Aroosa Shinde, Mrunal Bender, Onur Alshammari, Farhan Ansari, Mukhtar Anwar, Sirajudheen The SARS-CoV-2 mutations versus vaccine effectiveness: New opportunities to new challenges |
title | The SARS-CoV-2 mutations versus vaccine effectiveness: New opportunities to new challenges |
title_full | The SARS-CoV-2 mutations versus vaccine effectiveness: New opportunities to new challenges |
title_fullStr | The SARS-CoV-2 mutations versus vaccine effectiveness: New opportunities to new challenges |
title_full_unstemmed | The SARS-CoV-2 mutations versus vaccine effectiveness: New opportunities to new challenges |
title_short | The SARS-CoV-2 mutations versus vaccine effectiveness: New opportunities to new challenges |
title_sort | sars-cov-2 mutations versus vaccine effectiveness: new opportunities to new challenges |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8730674/ https://www.ncbi.nlm.nih.gov/pubmed/35042059 http://dx.doi.org/10.1016/j.jiph.2021.12.014 |
work_keys_str_mv | AT malikjonaidahmad thesarscov2mutationsversusvaccineeffectivenessnewopportunitiestonewchallenges AT ahmedsakeel thesarscov2mutationsversusvaccineeffectivenessnewopportunitiestonewchallenges AT miraroosa thesarscov2mutationsversusvaccineeffectivenessnewopportunitiestonewchallenges AT shindemrunal thesarscov2mutationsversusvaccineeffectivenessnewopportunitiestonewchallenges AT benderonur thesarscov2mutationsversusvaccineeffectivenessnewopportunitiestonewchallenges AT alshammarifarhan thesarscov2mutationsversusvaccineeffectivenessnewopportunitiestonewchallenges AT ansarimukhtar thesarscov2mutationsversusvaccineeffectivenessnewopportunitiestonewchallenges AT anwarsirajudheen thesarscov2mutationsversusvaccineeffectivenessnewopportunitiestonewchallenges AT malikjonaidahmad sarscov2mutationsversusvaccineeffectivenessnewopportunitiestonewchallenges AT ahmedsakeel sarscov2mutationsversusvaccineeffectivenessnewopportunitiestonewchallenges AT miraroosa sarscov2mutationsversusvaccineeffectivenessnewopportunitiestonewchallenges AT shindemrunal sarscov2mutationsversusvaccineeffectivenessnewopportunitiestonewchallenges AT benderonur sarscov2mutationsversusvaccineeffectivenessnewopportunitiestonewchallenges AT alshammarifarhan sarscov2mutationsversusvaccineeffectivenessnewopportunitiestonewchallenges AT ansarimukhtar sarscov2mutationsversusvaccineeffectivenessnewopportunitiestonewchallenges AT anwarsirajudheen sarscov2mutationsversusvaccineeffectivenessnewopportunitiestonewchallenges |